美罗培南与利奈唑胺治疗颅脑手术并颅内感染患者临床疗效的对比研究

Clinical Effect in Treating Patients with Intracranial Infection Caused by Craniocerebral Surgery between Meropenem and Linezolid:a Comparative Study

目的比较美罗培南与利奈唑胺治疗颅脑手术并颅内感染患者的临床疗效。方法选取2016年2月-2017年12月武汉市黄陂区人民医院收治的颅脑手术并颅内感染患者81例,采用随机数字表法分为对照组(n=40)和观察组(n=41)。在对症治疗基础上,对照组患者给予利奈唑胺治疗,观察组患者给予美罗培南治疗;两组患者均持续治疗8 d。比较两组患者临床总有效率、治疗前后炎性因子[包括红细胞沉降率(ESR)、降钙素原(PCT)反应蛋白(CRP)],并观察两组患者治疗期间不良反应发生情况。结果观察组患者临床总有效率高于对照组(P<0.05)。两组患者治疗前ESR、PCT、CRP比较,差异无统计学意义(P>0.05);观察组患者治疗后ESR、PCT、CRP低于对照组(P<0.05)。两组患者治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论与利奈唑胺相比,美罗培南可更有效地提高颅脑手术并颅内感染患者临床总有效率并减轻患者炎性反应,且未增加不良反应发生风险。

Objective To compare the clinical effect in treating patients with intracranial infection caused by craniocerebral surgery between meropenem and linezolid. Methods From February 2016 to December 2017,a total of 81 patients with intracranial infection caused by craniocerebral surgery were selected in the People’s Hospital of Huangpi District,Wuhan,and they were divided into control group(n=40) and observation group(n=41)according to random number table method. Based on symptomatic treatment,patients in control group were treated with linezolid,while patients in observation group were treated with meropenem;both groups continuously treated for 8 days. Total clinical effective rate,inflammatory cytokines(including ESR,PCT and CRP)before and after treatment were compared between the two groups,moreover incidence of adverse reactions was observed during treatment. Results Total clinical effective rate in observation group was statistically significantly higer than that in control group(P<0.05). No statistically significant difference of ESR,PCT or CRP was found between the two groups before treatment(P>0.05),while ESR,PCT and CRP in observation group were statistically significantly lower than those in control group after treatment(P>0.05). No statistically significant difference of incidence of adverse reactions was found between the two groups during treatment(P>0.05). Conclusion Compared to linezolid,meropenem can more effectively improve the total clinical effective rate and reduce the inflammatory reaction in treating patients with intracranial infection caused by craniocerebral surgery,without increasing the risk of adverse reactions.